Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute methylphenidate effects on attention, ocular measures, cognition, and driving
ACTRN12620000499987Phase 2Recruiting
- Sponsor
- Swinburne University of Technology
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Swinburne University of Technology. Primary endpoints: Digit vigilance cognitive performance, Driving performance: standard deviation of lateral position and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ACTRN12620000499987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000499987.